Dr. Michael D. Lieberman

Dr. Lieberman leads one of New York’s busiest academic gastrointestinal-oncology programs, integrating clinic, operating room, and translational laboratories under a single surgical service. At NewYork-Presbyterian/Weill Cornell he supervises fellows and residents while coordinating interdisciplinary protocols that pair image-guided resections with contemporary systemic therapy, ensuring that surgical decisions align with evolving molecular data and patient goals.

 

His investigative interests centre on peri-operative risk reduction and quality of life after complex abdominal surgery. Landmark analyses linked low hospital pancreatectomy volumes to excess mortality, informing regionalisation policies for pancreatic surgery nationwide. Subsequent laboratory work explored adenoviral gene delivery and cAMP-mediated growth inhibition in pancreatic cancer, laying early groundwork for gene-directed therapeutics. Recent contributions include multi-institutional studies of whole-genome signatures in acinar-cell carcinoma that refine homologous-recombination–deficient subsets amenable to targeted agents.

 

Consultations are structured in clear, jargon-free segments that review diagnosis, operative options, potential complications, and recovery milestones. Patients receive printed summaries and contact pathways for rapid clarification, a practice credited with high satisfaction scores and robust trial enrolment. Enhanced-recovery bundles emphasise early ambulation, opioid-sparing analgesia, and carbohydrate loading to accelerate functional return without compromising oncologic margins.